Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Glucose Monitoring Jun 21 | 2024EXCLUSIVE: FENIX Interview with CGM Newcomer Allez Health (Part 1)Purchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring, Insulin Delivery, Other Jun 20 | 2024Omnipod 5 Launch Updates; Zealand Ph1b MAD Petrelintide data; Ypsomed AID Algorithm Approved by FDA; Silence Ph2 siRNA Results; Lilly Fights Compounded Tirzepatide SalesPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, SGLT2i Jun 18 | 2024Merck Initiates Ph2a Efinopegdutide Trial in MASH; Lexicon Publishes Cost-Effectiveness Analysis of Inpefa; Novo, Tandem, and Altimmune to Present at ADA 2024Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Jun 17 | 2024JPMorgan Raises $500M Venture Fund for New Obesity TherapiesPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Jun 13 | 2024New Pfizer Obesity Partnership; FDA Lifts Vivani GLP-1RA Implant Clinical Hold; Novo Partners with Biosplice; Sagimet Denifanstat MASH Investor CallPurchase Blast
$599
Posted in: GLP-1RA, Other, SGLT2i Jun 12 | 2024Verily Launches CVRM Virtual Care Program; Sanders Questions Novo Drug Pricing; Farxiga Receives Pediatric Approval in USPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Jun 11 | 2024Syntis Bio Launches with Oral Anti-Obesity Therapy; Akero Initiates Ph3 SYNCHRONY Outcomes Trial in MASH; Merck Initiates H2H Ph3 Oral PCSK9i Trial; Nanexa Doses First Patient in New QM Liraglutide StudyPurchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring, Other Jun 10 | 2024FDA Clears Abbott’s Lingo and Libre Rio CGMs; Lilly Publishes SYNERGY-NASH Results; Teladoc Appoints New CEOPurchase Blast
$599
Posted in: Dual/triple agonist, Other Jun 07 | 2024BI Presents MASH Data at EASL 2024; Scholar Rock Initiates Ph2 Apitegromab Trial in Obesity; Biomea’s BMF-219 Placed on Clinical HoldPurchase Blast
$599
Posted in: Other Jun 06 | 2024Madrigal and Sagimet Present MASH Data at EASL 2024Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Jun 05 | 2024NICE to Recommend Tirzepatide for Obesity; Lilly and Altimmune MASH Data at EASL 2024; Lilly Initiates Ph1 Orforglipron Capsule vs. Tablet Bridging Study; Dexcom G7 Direct to Apple Watch Now AvailablePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Jun 05 | 2024CinRx Raises $73M to Fund its Startups, Including Obesity; Dexcom ONE Reimbursement for T2DM Patients in France; Viking Positive Ph2b Histology MASH Data; Lilly Initiates Ph3 SURMOUNT-ADOLESCENTS-2 TrialPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Jun 03 | 2024Novo Launches New Wegovy Campaign; Structure Reports Positive GSBR-1290 Topline Obesity DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other May 29 | 2024Tandem Mobi Integrated with Dexcom G7; Ro Launches GLP-1 Supply Tracker; Novartis Initiates Ph4 Inclisiran vs. BA H2H Study; AZ Ph1 Oral PCSK9i Results; Catalent Stockholders Approve Acquisition by NovoPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other May 29 | 2024May CHMP Agenda; Noom and Ro GLP-1RA Ads Observed; NewAmsterdam Lp(a) ResultsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other May 24 | 2024FDA Adcom Votes 4-7 Against Insulin Icodec T1DM ApprovalPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA May 24 | 2024Full FLOW Results at ERA; Lilly Increases Manufacturing Investment to $9BPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other May 23 | 2024Zealand Ph2a Dapiglutide Results; SixPeaks Launches as Obesity Startup with AZ Investment; Medtronic CY Q1 ’24 Earnings; Scholar Rock and Sagimet Investor Days; CLEAR Outcomes EU ApprovalPurchase Blast
$599
Posted in: Glucose Monitoring, Other May 22 | 2024New CGM Player to Enter the MarketPurchase Blast